The committee’s recommendations are forwarded to the Federal Ministry of Health for consideration.
Read moreAll other aspects of the voluntary scheme remain unchanged.
Read moreThe changes cover how topics are chosen, the steps and stages in each evaluation and how evidence is...
Read moreThe report looks at four possible scenarios including most notably the creation of a “grande Sécu...
Read moreThe Court has annulled the inclusion of the orphan drug Onivyde (irinotecan) in the reference price ...
Read moreThe association proposes concentrating efforts around four primary objectives.
Read moreAccording to the Institute for Quality and Efficiency in Health Care orphan drugs should undergo ear...
Read moreIn addition to new cancer drugs, the G-BA also evaluated the first antiviral drug to treat COVID-19 ...
Read moreNotably, the early access scheme was reformed with effect from 1st July 2021.
Read moreThe National Institute for Health and Care Excellence (NICE) on 31st January 2022 published its new ...
Read more